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A B S T R A C T
A 60-year-old man who was recently diagnosed with lung adenocarcinoma underwent 18F-FDG posi-
tron emission tomography/computed tomography (FDG PET/CT) scan for staging. The FDG PET/CT scan
showed incidental hypermetabolic uptake in the pituitary gland and focal hypermetabolic activity in the
left thyroid lobe. Histopathologic evaluation revealed these to be a non-functioning pituitary adenoma
and papillary thyroid cancer, respectively. Incidental hypermetabolic uptake in the pituitary and thyroid
glands on FDG PET/CT scan are uncommon. It is important to determine their etiologies as this may lead
in some cases to incorrect staging of the primary cancer and, therefore, inappropriate clinical manage-
ment. In this case report we will discuss the clinical presentation and the imaging ﬁndings of this patient
and review the related literature.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Positron emission tomography/computed tomography (PET/
CT) scan is commonly used to stage different types of malignancies.
However, incidental FDG PET/CT scan lesions can be found in up to
12% of patients [1] and work up of these incidental ﬁndings may
lead to a change in the clinical management of the primary cancer.
Incidental hypermetabolic thyroid nodules on PET scan are uncom-
mon with reported rates ranging from 0.8–4.9% [2–9]. Incidental
hypermetabolic PET lesions in the pituitary gland are even rarer, with
a reported incidence of 0.07–0.8% [10,11]. We present a case of a
patient presenting with lung cancer found to have both of these rare
incidental ﬁndings in the thyroid and pituitary glands. Both ﬁnd-
ings represented two different primary pathologies in addition to
the primary malignancy.
Case report
A 60-year-old man with no past medical history presented to
the emergency department with hypertensive urgency directly after
his initial visit with his new primary care physician. Chest X ray was
suspicious for aortic dissection. Computed tomography (CT) scan
ruled out aortic dissection; however, it revealed a spiculated 1.4 cm
nodule in the left lung lobe. Subsequent CT guided biopsy identi-
ﬁed the presence of adenocarcinoma.
The patient then underwent FDG PET/CT scan which showed a
hypermetabolic left upper lobe pulmonary nodule without other
lung lesions or lymphadenopathy. However, a hypermetabolic sellar
mass and a left thyroid lobe mass were also seen (Figure 1). The
maximum standardized uptake value (SUV) of the foci in the pitu-
itary and thyroid glands were 16.6 and 13.5 respectively and these
lesions are shown in Figures 2 and 3 respectively. A brain MRI done
thereafter showed a large heterogeneous enhancing expansile sellar
and suprasellar mass abutting and displacing the optic chiasm and
adjacent structures (Figure 4). Thyroid ultrasound showed a 1.5 cm
heterogeneous left nodule with ill-deﬁned borders (Figure 5). Pi-
tuitary hormones levels were unremarkable except for a slightly
elevated IGF-1 twice at 236 and 277 ng/ml (Reference range 81–
225, Table 1). Fine needle aspiration biopsy (FNAB) of the left thyroid
mass showed papillary thyroid carcinoma (Figure 6A). The patient
then underwent sublabial resection of the pituitary mass and im-
munohistochemical stains indicated that this was a non-functioning
adenoma (Figure 7). Subsequently, he underwent total thyroidec-
tomy for papillary thyroid carcinoma (Figure 6B).
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Discussion
Incidental FDG PET positive lesions can be encountered in the
process of staging patients with cancer at a rate of about 4.1–12%
[1,12–14]. Chopra et al. [13] reported that 9.2% of patients with sus-
pected or known lung cancer had incidental FDG PET/CT scan ﬁnding
and that 1.2% were malignant. Ishimori et al. [14] reported unex-
pected primary malignant tumors in 1.2% of patients with cancer
undergoing PET scan.
Incidental FDG PET/CT positivity in the pituitary is very rare with
an incidence rate of approximately 0.07–0.8% [10,11]. The etiolo-
gy of this varies and there are several reports of incidental PET lesions
correlating with pituitary adenomas and pituitary metastases
[15–20]. Jeong et al. [10] reviewed the ﬁles of more than 40,000pa-
tients who underwent whole body FDG PET/CT for assessment of
known or suspectedmalignancy excluding patients with prior history
of pituitary tumors. There were only 30 patients who had focal in-
creased FDG uptake in the pituitary gland (0.073%) [10]. In that study
[10] histological diagnosis was obtained from 3 patients revealing
2 growth hormone producing adenomas and 1 non-functioning
adenoma and there were no evidence of metastases to pituitary in
any of these patients in follow up. Hyun et al. [11] evaluated more
than 13,000patients who underwent FDG/PET/CT scan and found
incidental pituitary uptake in 107 patients (0.8%). Twenty nine out
of these 107 patients were determined to have a pathological uptake
with etiologies being macroadenoma (21 patients), microadenoma
(5 patients) and malignancy (3 patients) [11]. Both studies showed
a correlation between pathological uptake and size of adenoma and
the SUV value [10,11]. The patient in our case had a macroadenoma
with an uptake in the pituitary that had an SUV value of 16.6. This
is comparable to the data of Jeong et al. [10]. Hyun et al. [11] showed
an overall SUV value of 11.5 ± 8.4 and 10.9 ± 7 respectively in patients
Figure 1. Multiple hypermetabolic foci on PET scan (indicated by arrows).
Figure 2. Hypermetabolic focus on PET scan in pituitary gland.
Figure 3. Hypermetabolic focus on PET scan in left thyroid lobe.
Figure 4. MRI of brain showing large pituitary mass.
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with pituitary macroadenoma. Our patient was also determined
to have a non-functioning pituitary adenoma. Aside from slightly
elevated IGF-1, hormonal levels were normal and immunohisto-
chemical staining did not indicate a hyper-functioning adenoma. It
is not entirely clear why IGF-1 level was elevated; however, we
believe that this was a false elevation. In fact, Bancos et al. [21] re-
ported 4% incidence of falsely elevated IGF-1 and that in 65% of
patients with amedian follow up of 36months, the subsequent IGF-1
concentration was within reference interval. The cause of this false
elevation is not always known but could be related to pitfalls in
assays [22].
This case was also combined with another focus of PET positiv-
ity in the thyroid gland. Incidental PET positivity in the thyroid can
be either diffuse or incidental. Diffuse positivity is associated with
benign conditions such as thyroiditis [2]. Focal FDG PET/CT posi-
tivity in thyroid is less common with a rate of 0.8–4.9% [2–9,23];
however it carries a high risk of thyroid malignancy with a rate of
approximately 34–39.6% [3,23,24]. There is a considerable overlap
in SUV values between benign and malignant lesions to on the FDG
PET/CT [24,25] and therefore it is diﬃcult to rely on that in making
the determination that a lesion is malignant or not.
Since FDG PET/CT scan is usually done in the setting of a patient
with a known malignancy, the challenge with incidental ﬁndings
is to determine if these are metastatic disease, separate primary
cancers or benign incidental lesions. Metastases to the pituitary gland
are very rare with only 1% of all pituitary surgeries being per-
formed for that reason. Breast and lung cancers are the most
common cancers that metastasize to the pituitary [26]. The clini-
cal presentation of pituitarymetastases is usually asymptomatic with
only 7% presentingwith diabetes insipidus, themost common ﬁnding
[26]. Metastases to thyroid gland are also very rare, accounting for
only 1.4–3% of all thyroid malignancies [27] with kidney and lung
cancer being the most common primaries [28]. This incidence rate
is higher in autopsy studies [29]. The presentation could be inci-
dental lesion on imaging, palpable ﬁndings or sometimes with
compressive symptoms such as dyspnea or hoarseness [30].
The incidental FDG PET/CT scan ﬁndings may change the clin-
ical management in some patients with cancer. Therefore, clinical
judgment is essential to decide on further work up on these inci-
dental lesions. Staging of the primary malignancy and overall
prognosis can aide in deciding further investigation. In a patient with
an early stage primary malignancy where staging will be affected
by ﬁnding the etiology of the incidental lesion, thereby changing
the management and prognosis, a work up of this incidental ﬁnding
will be essential. Ishimori et al. reported that further evaluation of
incidental lesions was three times more likely to be done in pa-
tients with early-stage disease (stages 1 and 2) based on the
malignancy that was the indication for the performance of the FDG
PET/CT scan [14]. On the other hand, for a patient with advanced
cancer and widespread metastases, the work up of an incidental
ﬁnding may not be critical. The location of the incidental lesion is
also important. In the above case, our patient appeared to have ad-
enocarcinoma that was localized in the lung. Finding metastatic
disease in the thyroid and/or pituitary would have changed both
the staging of the cancer and subsequent clinical management. Also,
Figure 5. Thyroid ultrasound showing left thyroid nodule.
Table 1
Hormonal Lab Results
Patient’s Result Reference Range
TSH 0.663 uIU/ml* 0.55–4.78
Free T4 1.12 ng/dl 0.89–1.76
Growth Hormone <0.05 ng/ml <3
Insulin Growth Factor (IGF-1) 236 ng/ml 81–225
8 AM Cortisol 14.38 ug/dl 3.09–22.4
ACTH 18 pg/ml 9–50
Total Testosterone 284 ng/dl 241–827
LH 4.8 mIU/ml 1.5–9.3
FSH 10 mIU/ml <18
Prolactin 6.5 ng/ml 2.1–17.7
* TSH was done three times before surgery and levels ranged from 0.36 uIU/ml
to 0.76 uIU/ml. Free T4 was normal twice at 1.12 ng/dl and 1.3 ng/dl.
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hormonal evaluation was essential with the pituitary ﬁndings, as
this may have revealed hormonal abnormalities that would have
been critical to manage during treatment of the primarymalignancy.
Conclusion
This case describes the incidental ﬁndings of positive foci on PET
scan in the thyroid and pituitary glands in a patient with a known
malignancy. It emphasizes the importance of a complete work up
of these ﬁndings that may reveal other pathologies besides metas-
tases from the primary tumor in regards to management and
prognosis of malignancies.
Consent
Written informed consent was obtained from the patient for pub-
lication of this case report and accompanying images.
Conﬂict of interest
The authors reported no conﬂict of interest.
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